Abstract Background Consumption of Cannabis sativa derivatives has increased for their beneficial effects on pregnancy in reducing symptoms such as nausea, vomiting, insomnia and anxiety. However, FDA clearly strongly advises against the use of delta-9-tetrahydrocannabinol (THC) during pregnancy (Solowij et al., 2016). Aims 0.001) and in the sociability (p0.001), which alterations were paralleled by increased CB1R (p0.05) and DAGL-alfa (p0.05), D2DR (p0.05) and decreased FAAH (p0.05) mRNA levels, respectively. There were no changes in the % of cells peripheral blood leukocytes between VHC treated group and pTHC rats. Discussion & Conclusions Our data shows that prenatal THC exposure leads to anomalies at neonatal age which may be considered as early markers of neurodevelopmental disorders later in life characterized by cognitive and social impairment. Furthermore, the altered tone of the endocannabinoid/dopaminergic system, may be suggested as potential target for innovative pharmacological challenges.
Micale et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: